Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shionogi & Co ( (JP:4507) ) has issued an update.
Shionogi & Co., Ltd. released its fiscal 2025 financial results and provided forecasts for fiscal 2026, outlining its recent performance and expectations for the coming year. The company also detailed progress in its core businesses and development pipeline, signaling how current initiatives may support future growth.
In addition, Shionogi shared its roadmap toward achieving its 2030 vision, highlighting strategic priorities intended to strengthen its long-term competitive position. The company further addressed shareholder returns, indicating ongoing attention to capital allocation and investor value as it executes its longer-term plans.
The most recent analyst rating on (JP:4507) stock is a Hold with a Yen3300.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company focused on researching, developing, and marketing prescription drugs and related healthcare solutions. The company’s portfolio typically includes treatments for infectious diseases and other high-need therapeutic areas, positioning it as a key player in both domestic and global healthcare markets.
Average Trading Volume: 2,741,658
Technical Sentiment Signal: Buy
Current Market Cap: Yen2794.3B
See more insights into 4507 stock on TipRanks’ Stock Analysis page.